HAMBURG, Germany, Nov. 5, 2013 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN:DE0005664809) announced today that it has entered into an integrated research collaboration with The Leukemia & Lymphoma Society (“LLS”). Evotec will support one of LLS’s Screen-to-Lead Programs (“SLP”). In this collaboration, Evotec partners with LLS to support selected programmes and principal investigators with resources for high-throughput screening and optimisation of small molecules into drug-like compounds. Evotec delivers an industrialised, cutting-edge, comprehensive and unbiased drug discovery infrastructure to support innovation efficiency as part of a fully integrated solution.
Help employers find you! Check out all the jobs and post your resume.
